Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946996589> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2946996589 abstract "e15102 Background: TAS-102 is effective in refractory mCRC and significantly improved survival versus placebo. Currently no predictive biomarkers are established and used in clinical practice. Methods: We analyzed data of 160 patients treated with TAS-102 in real clinical practice in Czech Republic. Different factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated. Results: Baseline patients’ characteristics: median age 66 years (range 28-83), 106 patients were male (66.3 %), ECOG PS 0 had 38.1 %, RAS wt 45 %. Anti-VEGF treatment had 83.1 %, anti-EGFR 43.8 %. Median number of TAS-102 treatment line was 3 (range, 2 – 8), median TAS-102 cycles 3 (range 1 – 27). At the time of analysis 15 % continued in treatment, 73.7 % discontinued due to progression, 6.9 % due to toxicity, 3.8 % decided to discontinue in treatment. Median PFS was 3.3 months (95% CI, 3.0 – 3.5), and median OS 10.2 months (95% CI, 8.9 – 11.8). Factors significantly associated with PFS and/or OS were: PS, time from diagnosis of mCRC, initiation of TAS-102 treatment > 3 months from last fluoropyrimidine, baseline CRP, WBC, neutrophils count, monocytes count, NLR, neutropenia ≥ G2, diarrhea ≥ G1, thrombocytopenia ≥ G2, required TAS-102 dose reduction and cycle delay. We developed a scoring system TAScore from factors at the beginning of treatment (PS 0, initiation of TAS-102 > 3 months from fluoropyrimidine, time from diagnosis of mCRC, baseline CRP, WBC, monocytes count < 0.5 × 10 9 /L). For each factor patient received 1 point, the overall score was the sum of these points and patients were divided into 3 groups: high risk group with 0 to 1 point, intermediate with 2 to 3, favorable with 4 or more points. OS according to risk group was: 5.7 months for high risk (11 patients), 8.7 for intermediate (63), 12.8 for favorable (59) (P < 0.0001). TAScore was also associated with PFS: 2.4 months for high risk, 2.9 intermediate and 3.9 for favorable risk group (P < 0.0001). Conclusions: TAS-102 is effective in patients with refractory mCRC. We propose simple scoring system TAScore to help with precise patient selection at the beginning of TAS-102 treatment." @default.
- W2946996589 created "2019-06-07" @default.
- W2946996589 creator A5000705184 @default.
- W2946996589 creator A5025931905 @default.
- W2946996589 creator A5030927116 @default.
- W2946996589 creator A5034158569 @default.
- W2946996589 creator A5039214402 @default.
- W2946996589 creator A5039421731 @default.
- W2946996589 creator A5050754935 @default.
- W2946996589 creator A5060115847 @default.
- W2946996589 creator A5060489230 @default.
- W2946996589 creator A5061781467 @default.
- W2946996589 creator A5076719276 @default.
- W2946996589 creator A5086971449 @default.
- W2946996589 date "2019-05-20" @default.
- W2946996589 modified "2023-09-26" @default.
- W2946996589 title "Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic." @default.
- W2946996589 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15102" @default.
- W2946996589 hasPublicationYear "2019" @default.
- W2946996589 type Work @default.
- W2946996589 sameAs 2946996589 @default.
- W2946996589 citedByCount "1" @default.
- W2946996589 countsByYear W29469965892020 @default.
- W2946996589 crossrefType "journal-article" @default.
- W2946996589 hasAuthorship W2946996589A5000705184 @default.
- W2946996589 hasAuthorship W2946996589A5025931905 @default.
- W2946996589 hasAuthorship W2946996589A5030927116 @default.
- W2946996589 hasAuthorship W2946996589A5034158569 @default.
- W2946996589 hasAuthorship W2946996589A5039214402 @default.
- W2946996589 hasAuthorship W2946996589A5039421731 @default.
- W2946996589 hasAuthorship W2946996589A5050754935 @default.
- W2946996589 hasAuthorship W2946996589A5060115847 @default.
- W2946996589 hasAuthorship W2946996589A5060489230 @default.
- W2946996589 hasAuthorship W2946996589A5061781467 @default.
- W2946996589 hasAuthorship W2946996589A5076719276 @default.
- W2946996589 hasAuthorship W2946996589A5086971449 @default.
- W2946996589 hasConcept C121332964 @default.
- W2946996589 hasConcept C121608353 @default.
- W2946996589 hasConcept C126322002 @default.
- W2946996589 hasConcept C138885662 @default.
- W2946996589 hasConcept C142424586 @default.
- W2946996589 hasConcept C143998085 @default.
- W2946996589 hasConcept C2776248978 @default.
- W2946996589 hasConcept C2777842544 @default.
- W2946996589 hasConcept C41895202 @default.
- W2946996589 hasConcept C526805850 @default.
- W2946996589 hasConcept C71924100 @default.
- W2946996589 hasConcept C87355193 @default.
- W2946996589 hasConceptScore W2946996589C121332964 @default.
- W2946996589 hasConceptScore W2946996589C121608353 @default.
- W2946996589 hasConceptScore W2946996589C126322002 @default.
- W2946996589 hasConceptScore W2946996589C138885662 @default.
- W2946996589 hasConceptScore W2946996589C142424586 @default.
- W2946996589 hasConceptScore W2946996589C143998085 @default.
- W2946996589 hasConceptScore W2946996589C2776248978 @default.
- W2946996589 hasConceptScore W2946996589C2777842544 @default.
- W2946996589 hasConceptScore W2946996589C41895202 @default.
- W2946996589 hasConceptScore W2946996589C526805850 @default.
- W2946996589 hasConceptScore W2946996589C71924100 @default.
- W2946996589 hasConceptScore W2946996589C87355193 @default.
- W2946996589 hasLocation W29469965891 @default.
- W2946996589 hasOpenAccess W2946996589 @default.
- W2946996589 hasPrimaryLocation W29469965891 @default.
- W2946996589 hasRelatedWork W2239456084 @default.
- W2946996589 hasRelatedWork W2599097017 @default.
- W2946996589 hasRelatedWork W2758842849 @default.
- W2946996589 hasRelatedWork W2789605614 @default.
- W2946996589 hasRelatedWork W2802514896 @default.
- W2946996589 hasRelatedWork W2891075134 @default.
- W2946996589 hasRelatedWork W2908037605 @default.
- W2946996589 hasRelatedWork W2911730060 @default.
- W2946996589 hasRelatedWork W2914466538 @default.
- W2946996589 hasRelatedWork W2914842999 @default.
- W2946996589 hasRelatedWork W2944159393 @default.
- W2946996589 hasRelatedWork W2998254999 @default.
- W2946996589 hasRelatedWork W3010549632 @default.
- W2946996589 hasRelatedWork W3041836607 @default.
- W2946996589 hasRelatedWork W3089833732 @default.
- W2946996589 hasRelatedWork W3136733183 @default.
- W2946996589 hasRelatedWork W3165367024 @default.
- W2946996589 hasRelatedWork W3166456074 @default.
- W2946996589 hasRelatedWork W3177570662 @default.
- W2946996589 hasRelatedWork W3198655926 @default.
- W2946996589 isParatext "false" @default.
- W2946996589 isRetracted "false" @default.
- W2946996589 magId "2946996589" @default.
- W2946996589 workType "article" @default.